Compare Abeona Therapeutics Inc (ABEO) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Apollo Global Management Ord Shs — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Apollo Global Management Ord Shs trades at $118.11 (market cap $68.80B). The key difference: Apollo Global Management Ord Shs is far larger — about 184.3× Abeona Therapeutics Inc's market cap, and Apollo Global Management Ord Shs pays a 1.89% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | APO | |
|---|---|---|
Market Cap | $373.32M | $68.80B |
Sector | Health | Financials |
52-Week High | $7.23 | $156.05 |
52-Week Low | $4.17 | $100.30 |
Enterprise Value | $228.22M | -$168.77B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Apollo Global Management (APO) trades at $119.33, up 0.61% with a bearish technical signal despite strong analyst consensus. The company reported Q1 2026 EPS of $1.94, beating expectations, and maintains a 95.15% gross margin. Recent news highlights liquidity pressures in private credit funds, with Apollo capping withdrawals from its $25 billion Apollo Debt Solutions fund after 17% redemption requests in Q2 2026.
Outlook remains mixed: strong fee-generating AUM growth and dividend increases support bullish analyst targets averaging $149.71, but near-term risks include private credit liquidity concerns and multiple law firm investigations. The stock offers 25% upside to consensus target if liquidity pressures ease and earnings meet guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
